

Taking Point of Care to New Heights



Talis Corporate Presentation

May 2022



Disclaimer



The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations, financial condition, business strategy, plans, and objectives of management for future operations of the Company are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Talis Biomedical (“Talis,” “we,” “our”) has based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to address business challenges, deploy capital effectively, align resources and preserve cash; our ability to position Talis for future success; the next steps and timing to commercially launch our Talis One system; our ability to complete the post-market study required under the terms of the EUA for the Talis One COVID-19 Test System; our ability to align resources and extend our cash runway; or our expectation regarding expense savings. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business of the ongoing COVID-19 pandemic, including any impact on our ability to market our products (including any third-party products we may offer), demand for our products due to deferral of procedures using our products or disruption in our supply chain, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, maintenance of coverage and adequate reimbursement for procedures using our products, product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this presentation speak only as of the date of this press release, and Talis assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this presentation, except as required under applicable law.

This presentation also contains estimates and information concerning our industry and business, including estimated market size and projected growth rates of the markets in which Talis participates. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Talis has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, we cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of our future performance and the future performance of the industries in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Talis.

Diagnostic Testing is Shifting to the Point-of-Care (POC)



Inherent clinical advantage

Accurate, immediate treatment reduces empirical prescribing, office visits and patients lost to follow-up



COVID accelerating POC platform adoption

Creates channel for broader infectious disease testing at the point-of-care




Economic Benefit

Shifts reimbursement to those providing care

Talis is Well-Positioned to Lead Shift from Central Labs to POC

The Talis One™ System is designed to deliver rapid, accurate and accessible testing with established clinical benefit in large infectious disease markets at the POC



Successful POC Testing Requires Confluence of 5 Capabilities



**Sensitivity &
Specificity**



**Rapid
Turnaround**



**Ease of Use /
Untrained Users**



**Extensible
Test Menu**



Low Cost

The Talis One System is Designed to Deliver All Five



Talis One Point-of-Care Testing System



The Technology



* The Talis One COVID-19 Test System is for use under Emergency Use Authorization (EUA) only.

Modular Test Cartridge Enables Sample Prep, Menu Expansion



**Self-contained,
single-use consumable**

Wide Range of
Sample Input Volume

Sample Metering
and Measurement

Solid phase
DNA/RNA Extraction

Primers and probes on
individual reagent plugs

Flexible Multiplexing:
of wells, size

Designed for rapid menu
expansion, up to 14 targets



Instrument Designed for Capability, Cost and Ease-of-Use



Low Cost

Designed for
Untrained User

Amplicon
Containment

Cloud
Connectivity

Flexible
Multiplexing



3 Simple Steps

To accurate, rapid results



1 Label with patient ID:
Barcode or handwritten



2 Add specimen
to cartridge



3 Insert cartridge
into instrument



 **Results**


Scalable, Low-Cost Manufacturing to Address Large Markets



Scale drives gross margin expansion,
decreases COGs over time



>\$100M investment in automated
manufacturing to target 5,000 instruments
and 1M tests/month at full scale



Established supply chain



Talis One Delivers Clinical and Economic Value to Physicians



Saving Money and Time without Compromising Care



Low capital, labor costs



No additional cost to healthcare system



Pricing below established CPT codes




Redistributes revenue from central lab to POC




Go-to-Market: Focus on Placements that Value Menu



ESTABLISH FOOTPRINT FOR LONG-TERM INFECTIOUS DISEASE TESTING AT THE POINT-OF-CARE



EXPAND TEST MENU




Not All POC Tests are Created Equal



Important Questions to Ask	Talis One
Does it include sample preparation to ensure accuracy?	✓
Does it have a limit of detection below 1,000 viral particles per mL ?	✓
Can it generate a result in less than 30 minutes while the patient is in the office?	✓
Can an untrained user operate?	✓
Is there ability to detect multiple organisms from a single specimen?	✓
Does it provide a menu to address multiple infectious disease testing needs?	✓
Can it be produced at scale for low cost?	✓

Planned Menu Expansion

Paving the Way to Future Growth



Talis Highlights



Improved quality of care and economics by shifting diagnostic testing from centralized labs to point-of-care



Large addressable market and growing



Talis One System delivers confluence of accuracy, speed, ease of use, extensible menu and low cost



Strongly-positioned to drive revenue by menu expansion and automation with promising pipeline for accelerated growth



Well-capitalized to execute strategy with ~\$188M in cash and cash equivalents

Thank You

